WHO ICTRP trial
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial to…
DRKS00015967 · German Clinical Trials Register · Recruiting
Key facts
| Trial ID | DRKS00015967 |
|---|---|
| Public title | A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial to Evaluate Efficacy and Safety of Lenabasum in Cystic Fibrosis |
| Scientific title | A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial to Evaluate Efficacy and Safety of Lenabasum in Cystic Fibrosis |
| Primary sponsor | Corbus Pharmaceuticals |
| Registry | German Clinical Trials Register |
| Recruitment status | Recruiting |
| Study type | interventional |
| Phase | 3 |
| Countries | Austria;Australia;Belgium;Bulgaria;Canada;Czechia;Germany;Spain;France;United Kingdom;Greece;Hungary;Italy;Lithuania;Netherlands;Poland;Portugal;Réunion;Romania;Serbia;Russia;Sweden;Slovakia;Ukraine;U… |
| Conditions | E84.0;Cystic fibrosis with pulmonary manifestations;E84.0 |
| Interventions | Group 1: Lenabasum 20 mg BID, n=166 Group 2: Lenabasum 5mg BID, n=83 Group 3: Placebo BID, n=166 |
| Registration date | Apr 12, 2018 |
| Target size | 415 |
| Secondary IDs | NCT03451045;2017-003723-29 |
| Registry page | drks.de |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: